Cessation of smoking and vaping in participants who did and did not use varenicline
| Used varenicline (n=80) | Did not use varenicline (n=124) | P value, RR and 95% CI | |
| Stopped smoking | |||
| 3M – past 7 days | 43.8% (35) | 8.9% (11) | P<0.001, RR=4.9 (2.7 to 9.1) |
| 3M – past 30 days | 32.5% (26) | 5.6% (7) | P<0.001,RR=5.8 (2.6 to 12.6) |
| 6M – past 7 days | 31.3% (25) | 10.5% (13) | P<0.001, RR=3.0 (1.6 to 5.5) |
| 6M – past 90 days† | 17.5% (14) | 4.8% (6) | P=0.006, RR=3.6 (1.4 to 9.0) |
| Stopped vaping | |||
| 3M – past 7 days | 23.8% (19) | 3.2% (4) | P<0.001, RR=7.4 (2.6 to 20.9) |
| 3M – past 30 days | 18.7% (15) | 1.6% (2) | P<0.001, RR=11.6 (2.7 to 49.5) |
| 6M – past 7 days | 25% (20) | 3.2% (4) | P<0.001, RR=10.3 (3.2 to 33.6) |
| 6M – past 90 days | 12.5% (10) | 1.6% (2) | P=0.007, RR=7.8 (1.7 to 34.5) |
| Stopped both* | |||
| 3M – past 7 days | 11.3% (9) | 0.8% (1) | P=0.01, RR=14.0 (1.8 to 108.1) |
| 3M – past 30 days | 8.8% (7) | 0.8% (1) | P=0.02 RR=10.9 (1.4 to 86.6) |
| 6M – past 7 days | 11.3% (9) | 0.8% (1) | P=0.01, RR=14.0 (1.8 to 108.1) |
| 6M – past 90 days | 8.8% (7) | 0.8% (1) | P=0.02, RR=10.9 (1.4 to 86.6) |
*Only participants who passed cotinine validation are included.
†Primary outcome.